Entera Bio Shares Surge 52% After FDA Clears 750-Patient Phase 3 Trial Design
ENTX•Shares of Entera Bio jumped 52% on Monday, marking its largest one-day gain since March 2021, after the FDA backed its single Phase 3 trial design for EB613 in 750 postmenopausal osteoporosis patients. The registrational study will measure 12-month hip bone density improvements, compare oral EB613 to injectable Forteo, and begins late 2026 with top-line results expected in H2 2028, a year ahead of prior guidance.
1. FDA Alignment on Trial Design
Entera received FDA feedback endorsing a single registrational Phase 3 trial for EB613, enrolling roughly 750 postmenopausal osteoporosis patients and supporting future NDA submission.
2. Trial Structure and Endpoints
The trial will use 12-month hip bone mineral density as its primary endpoint, include a head-to-head comparison with injectable Forteo, and enroll a subset of patients in a bone biopsy sub-study to assess mechanism of action.
3. Timeline and Acceleration
Entera plans to initiate the study in late 2026 and expects topline results in the second half of 2028, accelerating its previous timeline by about one year and potentially advancing its regulatory path for the first oral anabolic osteoporosis drug.
4. Market Reaction
Following the FDA alignment news, Entera Bio shares surged 52%, setting up its largest one-day gain since March 2021, while retail investor sentiment on social platforms shifted from bullish to extremely bullish with elevated message volume.
